Can losartan reduce fibrosis and slow the decline of kidney function in kidney transplant patients?
Phase 1
Completed
- Conditions
- Allograft nephritisUrological and Genital Diseases
- Registration Number
- ISRCTN15884223
- Lead Sponsor
- Shahid Beheshti Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
1. First kidney transplantation of living unrelated donor
2. Compliance to losartan
3. No allergic reaction to losartan
4. Agreement to participate in the study
Exclusion Criteria
1. Second transplant
2. Cadaveric transplant
3. Acute rejection during first week after transplantation
4. Delayed graft function during first week after transplantation
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Graft function is determined by measuring eGFR at 48 hours, 3 and 6 months post transplantation<br>2. Fibrosis is measured by measuring TGF-ß and miR 21 levels using real time PCR at 48 hours, 3 and 6 months post transplantation
- Secondary Outcome Measures
Name Time Method o secondary outcome measures.